If You Invested in Rhythm Pharmaceu (RYTM)

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company that focuses on therapies for rare neuroendocrine diseases. According to company disclosures, Rhythm’s work centers on conditions where disruption of the melanocortin-4 receptor (MC4R) pathway leads to hyperphagia and severe obesity. The company’s lead asset is IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity in specific genetically defined patient populations. Rhythm is headquartered in Boston, Massachusetts and its common stock trades on the Nasdaq Global Market.

Core business and lead product

Rhythm describes itself as a global commercial-stage biopharmaceutical company. Its primary commercial product is IMCIVREE (setmelanotide). Setmelanotide is characterized by the company as an MC4R agonist designed to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients with certain rare forms of syndromic or monogenic obesity.

In the United States, company materials state that setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to:

• Bardet-Biedl syndrome (BBS)
• Pro-opiomelanocortin (POMC) deficiency, including proprotein convertase subtilisin/kexin type 1 (PCSK1)
• Leptin receptor (LEPR) deficiency

These indications require determination by an FDA‑approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS), as described in Rhythm’s public communications.

International indications and access

Rhythm reports that both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and control of hunger associated with:

• Genetically confirmed Bardet-Biedl syndrome (BBS)
• Genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency
• Biallelic LEPR deficiency

These authorizations apply in adults and children 2 years of age and above, and Rhythm notes that in the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with an underlying genetic etiology.

In Canada, Rhythm states that IMCIVREE (setmelanotide solution for subcutaneous injection) is indicated for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome or genetically confirmed biallelic POMC, PCSK1, or LEPR deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. The company has also disclosed public reimbursement agreements for IMCIVREE in several Canadian provinces and under the Federal Non‑Insured Health Benefits Program for eligible patients with obesity due to BBS.

Pipeline and research focus

Beyond its approved indications, Rhythm reports that it is advancing a broad clinical development program for setmelanotide in additional rare diseases. These include:

• Acquired hypothalamic obesity (HO), supported by the Phase 3 TRANSCEND trial in patients with acquired HO
• Congenital hypothalamic obesity, through a Phase 3 trial substudy
• Genetically caused MC4R pathway diseases, through the Phase 3 EMANATE trial
• Prader-Willi syndrome (PWS), where an exploratory Phase 2 trial has shown preliminary signals in body mass index (BMI) and hyperphagia measures

Rhythm also highlights two investigational MC4R agonists:

• Bivamelagon, an oral MC4R agonist evaluated in a Phase 2 trial in patients with acquired hypothalamic obesity
• RM-718, a weekly MC4R agonist studied in Phase 1 trials, including parts enrolling patients with acquired hypothalamic obesity and Prader-Willi syndrome

In addition, Rhythm states that it is advancing a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.

Therapeutic areas and disease focus

Across its programs, Rhythm concentrates on rare neuroendocrine diseases characterized by severe obesity and hyperphagia related to MC4R pathway dysfunction. Company materials describe work in:

• Bardet-Biedl syndrome (BBS), a rare autosomal recessive ciliopathy that can include hyperphagia, early-onset severe obesity and other systemic manifestations
• Monogenic forms of obesity due to POMC, PCSK1 or LEPR deficiency
• Acquired hypothalamic obesity, a rare form of obesity associated with hypothalamic injury and MC4R pathway disruption
• Prader-Willi syndrome, a rare genetic disorder associated with constant hunger, obesity and behavioral challenges

In its public descriptions, Rhythm emphasizes that these conditions involve profound unmet medical needs, particularly in relation to hyperphagia, severe obesity and associated complications.

Regulatory and clinical milestones

Rhythm’s disclosures describe multiple regulatory interactions and milestones. The company has submitted a supplemental New Drug Application (sNDA) in the United States seeking approval of setmelanotide for conditions associated with acquired hypothalamic obesity. The U.S. Food and Drug Administration (FDA) granted Priority Review and later extended the Prescription Drug User Fee Act (PDUFA) goal date to March 20, 2026. In parallel, the European Medicines Agency (EMA) validated a Type II variation to the Marketing Authorization Application for setmelanotide in acquired hypothalamic obesity, initiating review by the Committee for Medicinal Products for Human Use.

Rhythm has also reported that the Phase 3 TRANSCEND trial in acquired hypothalamic obesity met its primary endpoint of mean percent change in BMI at 52 weeks, and that setmelanotide was generally well tolerated in this study. The company has described additional analyses from TRANSCEND, including cardiometabolic parameters and patient- and caregiver‑reported outcomes, in scientific presentations.

Commercial activity and geographic reach

Rhythm characterizes itself as a global commercial-stage company. It reports net product revenues from global sales of IMCIVREE, with contributions from the United States and international markets. The company has described commercial efforts in Bardet-Biedl syndrome and monogenic obesity indications, as well as steps to secure reimbursement and access in various jurisdictions, including Canada and European markets.

Safety information and limitations of use

Company communications include detailed safety information and limitations of use for setmelanotide. Rhythm notes that setmelanotide is not indicated for:

• Obesity due to suspected POMC, PCSK1 or LEPR deficiency where variants are classified as benign or likely benign
• Other types of obesity not related to Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity

Contraindications include prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Reported warnings and precautions include disturbance in sexual arousal, depression and suicidal ideation, hypersensitivity reactions, skin hyperpigmentation and changes in melanocytic nevi, and risks related to benzyl alcohol preservative in neonates and low birth weight infants. Rhythm also highlights considerations for pediatric use, pregnancy and breastfeeding, and notes that the most common adverse reactions (incidence ≥20%) have included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression and spontaneous penile erection.

Corporate and capital markets information

Rhythm Pharmaceuticals, Inc. is incorporated in Delaware and lists its common stock on the Nasdaq Global Market under the symbol RYTM. The company has filed current reports on Form 8‑K describing financial results, regulatory milestones, equity offerings and amendments to its certificate of incorporation. In one such filing, Rhythm reported an underwritten public offering of common stock and stated that it intended to use the net proceeds to advance clinical development of its product candidates, support commercialization activities for IMCIVREE, and for working capital and general corporate purposes.

Position within pharmaceutical preparation manufacturing

Within the pharmaceutical preparation manufacturing industry, Rhythm’s activities are concentrated in biopharmaceutical research, development, regulatory interaction and commercialization for rare neuroendocrine diseases involving MC4R pathway dysfunction. Its portfolio, as described in public materials, spans an approved injectable therapy (IMCIVREE), late‑stage clinical programs in additional indications, oral and weekly MC4R agonists in development, and preclinical small molecules for congenital hyperinsulinism.